<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Life Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DC247267-DA2E-47CD-838A-348F17241C68"><gtr:id>DC247267-DA2E-47CD-838A-348F17241C68</gtr:id><gtr:firstName>Nancy</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Rothwell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G19%2F24"><gtr:id>6724A227-74EC-403F-998E-E739E5234AB4</gtr:id><gtr:title>Neuroimmune interactions in the brain [Professorship Award]</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G19/24</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Neuroimmune interactions in the brain</gtr:technicalSummary><gtr:fund><gtr:end>2008-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1998-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>474768</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amgen Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Provision of Amgen IL-1RA for clinical studies</gtr:description><gtr:id>9FEBE060-3333-4D20-9A3C-D357A5E28423</gtr:id><gtr:impact>Pharmacokinetic study identified optimal dosing regime of IL-1RA in SAH patients to take forward to test efficacy in further trials. Phase II randomised controlled double blind trial (IL-1RA vs placebo) now completed in SAH patients (analysis in progress).</gtr:impact><gtr:outcomeId>8751115D3FF-1</gtr:outcomeId><gtr:partnerContribution>Provision of IL-1RA for clinical studies</gtr:partnerContribution><gtr:piContribution>Carried out pharmacokinetic study to identify optimal dosing regime of IL-1RA in SAH patients.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Keynote lecture to Schools Science Conference 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>8F3298AF-E62F-42B6-A965-AB9569400B43</gtr:id><gtr:impact>Talk followed by Q&amp;amp;A session. Title: &amp;quot;A stroke of bad luck - new discoveries in the treatment of brain disease&amp;quot;. Session: Science is the Future.
Venue : Royal College of Pathologists, London
Audience : 50 secondary year students from years 10-13 and their teachers

No specific impact known.</gtr:impact><gtr:outcomeId>Lk5nSPG9mMS</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World Stroke Day 2011</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>5630E7C7-2726-4327-86CB-470CBA55087F</gtr:id><gtr:impact>Had several interactive stands/displays showing different aspects of our preclinical research, at World Stroke Day event in Oct. 2011 organised by our clinical colleagues. The audience comprised ~180 stroke patients and their carers, healthcare professionals and associated charities/organisations.

Not known.</gtr:impact><gtr:outcomeId>JTZokpxRk2b</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture at the University of Birmingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>5EFAF8B1-9FEB-4AD7-9E76-B1222A3EC4F7</gtr:id><gtr:impact>Talk title: &amp;quot;A stroke of bad luck: mechanisms and treatments for brain disease&amp;quot;. For ~200 Uni staff and students. Followed by questions and discussion.

No specific impact known.</gtr:impact><gtr:outcomeId>r8vUB86TSKs</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual STARS lecture, Manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>8CC94FDF-3472-4A16-8192-37D0F31AE796</gtr:id><gtr:impact>Annual STARS lecture to ~200 local sixth form and college students.
Title: 'A stroke of bad luck: Understanding brain disease' (targeted at A level Biology).

Not known.</gtr:impact><gtr:outcomeId>PFRnDs3rxGz</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>All types and numerous locations; numerous examples</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>CAC10CFE-6DA8-4BBC-BB53-180BB626ED9D</gtr:id><gtr:impact>Numerous scientific, public and policy talks - too many to detail.

Significant press coverage</gtr:impact><gtr:outcomeId>32113AF531B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Frontiers of Science talk, Uni of Manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>06C08C32-F5DA-4183-BBDC-51E8202DBF1B</gtr:id><gtr:impact>Frontiers of Science talk delivered to ~150 undergraduate students from 1st year to 3rd year, followed by questions and discussion. 
Title: &amp;quot;Flaming brains - new discoveries about brain disease&amp;quot;


No specific impact known.</gtr:impact><gtr:outcomeId>C55QFTfaDfg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Give approx. 10-12 public and schools lectures each year (too numerous to detail)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>D0939AEF-FE73-4C81-843E-094F449C22DD</gtr:id><gtr:impact>Give approx. 10-12 public and schools lectures each year (too numerous to detail)

Not possible to detail specific impacts - aim to increase interest in science, particularly in underprivileged areas. Often receive requests from school students wishing to do work experience in the lab, following a talk at their school (all of whom we aim to accommodate wherever possible).</gtr:impact><gtr:outcomeId>8455F4C626C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Numerous scientific, public and policy talks - too many to detail</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>C8DEA3B0-609E-4809-97CD-6D063679B83D</gtr:id><gtr:impact>Numerous scientific, public and policy talks - too many to detail.

Significant press coverage</gtr:impact><gtr:outcomeId>1716FB71527</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>640000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Models of Disease Grant</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0801040</gtr:fundingRef><gtr:id>CF3896D0-F361-4B9C-9EDD-20D2F07F6806</gtr:id><gtr:outcomeId>188400202F00</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developmental Clinical Studies</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1001252</gtr:fundingRef><gtr:id>91903A48-9556-4E52-AEDC-3BCEFE05BEF4</gtr:id><gtr:outcomeId>Dt7ETj7QHm60</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Collaboration with Amgen Inc. to test the clinical utility of IL-1RA for stroke in man. The first clinical phase II study was completed in 2004. Patent granted initially in US in 2000; other international applications went to grant in 2002, 2003, 2004 and 2008.</gtr:description><gtr:grantRef>G19/24</gtr:grantRef><gtr:id>127DA740-7B5C-490B-B293-41AE4521BFD6</gtr:id><gtr:impact>The data gathered suggest that rhIL-1RA is safe and well tolerated in acute stroke. In addition, rhIL-1RA exhibited biological activity that is relevant to the pathophysiology and clinical outcome of ischaemic stroke. These data demonstrate that rhIL- 1RA has potential as a new therapeutic agent for acute stroke. A pharmacokinetic study of IL-1RA in SAH patients has just been completed(Experimental Medicine grant G0502030).</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>D708FE89D39</gtr:outcomeId><gtr:patentId>WO9308820</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>New use for IL-1RA to treat neurodegeneration</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Advisory Committee on Science and Research in DoH</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>A8A179F4-AA49-44A0-B60E-EEA919EF08A4</gtr:id><gtr:impact>Member, Advisory Committee on Science and Research in
the Department of Health, Chaired by Sir David King.
Advised on how to better bring science into all aspects of
research in DoH.</gtr:impact><gtr:outcomeId>PcmG8Fw9N3B</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Major revisions to planned legislation on animal experiments</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>C7C1E06A-6255-4419-876A-34CA3A645297</gtr:id><gtr:impact>Co-chair, Bioseciences sector group bringing together
academia and industry to revise the European 86/609
planned legislation on animal experiments.
Major revisions to the planned legislation.</gtr:impact><gtr:outcomeId>riX9vqd6ooy</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>57CEA72B-F061-4D15-A454-1458A6A07DF7</gtr:id><gtr:title>Potential surrogate markers of cerebral microvascular angiopathy in asymptomatic subjects at risk of stroke.</gtr:title><gtr:parentPublicationTitle>European radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/022d83f7edc48eda1ccaae4240bcd5ab"><gtr:id>022d83f7edc48eda1ccaae4240bcd5ab</gtr:id><gtr:otherNames>Selvarajah J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0938-7994</gtr:issn><gtr:outcomeId>1F9FE77F3E3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AF0E571-C1B5-4FE9-8BD9-8E40DAB2F7AE</gtr:id><gtr:title>Cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d3e194b1caac581a3ee75169d19ffbb"><gtr:id>6d3e194b1caac581a3ee75169d19ffbb</gtr:id><gtr:otherNames>Bano D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>5A7A61EA47B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7171318F-0B1D-4E05-A9DC-8E2E8C498C08</gtr:id><gtr:title>Integrin-binding RGD peptides induce rapid intracellular calcium increases and MAPK signaling in cortical neurons.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ad40c8e1e8583fcf4ef6b503935330c"><gtr:id>7ad40c8e1e8583fcf4ef6b503935330c</gtr:id><gtr:otherNames>Watson PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn><gtr:outcomeId>58BA3C53EA4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35B8BEAE-F12F-4A40-8F0C-A05F393910AF</gtr:id><gtr:title>Chronic systemic infection exacerbates ischemic brain damage via a CCL5 (regulated on activation, normal T-cell expressed and secreted)-mediated proinflammatory response in mice.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5bb30e58633b002321fd2baac889f0a"><gtr:id>e5bb30e58633b002321fd2baac889f0a</gtr:id><gtr:otherNames>D?nes A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>DZdqkATuh2K</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C4557A5-9631-4EA0-A1F4-50A4726525E4</gtr:id><gtr:title>Inflammation in human brain injury: intracerebral concentrations of IL-1alpha, IL-1beta, and their endogenous inhibitor IL-1ra.</gtr:title><gtr:parentPublicationTitle>Journal of neurotrauma</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/783c2d727ee166ac861102bdf24a11b1"><gtr:id>783c2d727ee166ac861102bdf24a11b1</gtr:id><gtr:otherNames>Hutchinson PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0897-7151</gtr:issn><gtr:outcomeId>0F0DE9D5223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3EC07C2-0A81-4058-8CB9-0874552A05A0</gtr:id><gtr:title>Psychoneuroimmunology of stroke.</gtr:title><gtr:parentPublicationTitle>Neurologic clinics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/544bec4bb0cf8ed5109a40cd1bcd0fe6"><gtr:id>544bec4bb0cf8ed5109a40cd1bcd0fe6</gtr:id><gtr:otherNames>Skinner R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0733-8619</gtr:issn><gtr:outcomeId>AE56B387D70</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CB3B978-EEDF-4106-ABDE-2EC24C5B1065</gtr:id><gtr:title>Improving outcome after stroke: overcoming the translational roadblock.</gtr:title><gtr:parentPublicationTitle>Cerebrovascular diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19771b1402cf067b933ac5b291e56455"><gtr:id>19771b1402cf067b933ac5b291e56455</gtr:id><gtr:otherNames>Endres M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1015-9770</gtr:issn><gtr:outcomeId>1072E9B29BE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18798E21-C906-47AA-B901-E5C1F881E891</gtr:id><gtr:title>Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe1623bf82213855fcbc6ec544116a90"><gtr:id>fe1623bf82213855fcbc6ec544116a90</gtr:id><gtr:otherNames>Gueorguieva I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>D70614F1B09</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B30EDE8-4A78-402E-9903-C91C6E1A8ACA</gtr:id><gtr:title>Interleukin-6 and acute ischaemic stroke.</gtr:title><gtr:parentPublicationTitle>Acta neurologica Scandinavica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cec921b16e9ce0d167df6e911954968b"><gtr:id>cec921b16e9ce0d167df6e911954968b</gtr:id><gtr:otherNames>Emsley HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0001-6314</gtr:issn><gtr:outcomeId>07E2F5A3ED2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3F138F2-3506-4DA3-91B8-257A17566835</gtr:id><gtr:title>NF-kappaB activation by the Toll-IL-1 receptor domain protein MyD88 adapter-like is regulated by caspase-1.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e37ceaf1c2a419ca2898a51e26d6998"><gtr:id>7e37ceaf1c2a419ca2898a51e26d6998</gtr:id><gtr:otherNames>Miggin SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>BEFC6ADB0B3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9ACCDBE-0564-4AA5-B6A4-5F21F7A8B2A8</gtr:id><gtr:title>Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4f409f250b4b1959242bf8c5770b4e4"><gtr:id>b4f409f250b4b1959242bf8c5770b4e4</gtr:id><gtr:otherNames>Clark SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>365E3C60F22</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB55C521-5954-4201-9F73-1E20F421382E</gtr:id><gtr:title>Variability of the systemic acute phase response after ischemic stroke.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96b97ef1a88f6699dbff7bc9113ed7db"><gtr:id>96b97ef1a88f6699dbff7bc9113ed7db</gtr:id><gtr:otherNames>Smith CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>322D6A67D4B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C49EC6E7-6E40-40BB-9C36-135BBCD13CBC</gtr:id><gtr:title>Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production.</gtr:title><gtr:parentPublicationTitle>BMC neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cec921b16e9ce0d167df6e911954968b"><gtr:id>cec921b16e9ce0d167df6e911954968b</gtr:id><gtr:otherNames>Emsley HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1471-2377</gtr:issn><gtr:outcomeId>AA0A1EF4B59</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DEDF8A7-45CE-43F9-AA66-B693287DF781</gtr:id><gtr:title>The role of inflammation in CNS injury and disease.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4e5e584d7ebd517fb39a4181d2aa698"><gtr:id>d4e5e584d7ebd517fb39a4181d2aa698</gtr:id><gtr:otherNames>Lucas SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>59EEEF153C9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2173CE0-66BB-4762-82D6-EC4207C91BFA</gtr:id><gtr:title>A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cec921b16e9ce0d167df6e911954968b"><gtr:id>cec921b16e9ce0d167df6e911954968b</gtr:id><gtr:otherNames>Emsley HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>A27F9FBA946</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G19/24</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>